Page
%P
-
Article
Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy
The discovery of effective therapeutic treatments for cancer via cell differentiation instead of antiproliferation remains a great challenge. Cyclin-dependent kinase 2 (CDK2) inactivation, which overcomes the ...